Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?

Sternlicht, Hillel; Bakris, George L

Sternlicht, Hillel; Bakris, George L.

Affiliation

Sternlicht H; Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, ASH Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL, USA.

Blood Purif ; 41(1-3): 139-43, 2016.

Article in En | MEDLINE | ID: mdl-26766168

Subject(s)

Albuminuria/epidemiology; Angiotensin Receptor Antagonists/therapeutic use; Angiotensin-Converting Enzyme Inhibitors/therapeutic use; Diabetes Mellitus, Type 1/epidemiology; Diabetes Mellitus, Type 2/epidemiology; Diabetic Nephropathies/epidemiology; Hypertension/epidemiology; Albuminuria/drug therapy; Albuminuria/physiopathology; Blood Pressure/drug effects; Comorbidity; Diabetes Mellitus, Type 1/drug therapy; Diabetes Mellitus, Type 1/physiopathology; Diabetes Mellitus, Type 2/drug therapy; Diabetes Mellitus, Type 2/physiopathology; Diabetic Nephropathies/drug therapy; Diabetic Nephropathies/physiopathology; Disease Management; Humans; Hypertension/drug therapy; Hypertension/physiopathology; Practice Guidelines as Topic; Randomized Controlled Trials as Topic

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Angiotensin-Converting Enzyme Inhibitors / Diabetes Mellitus, Type 1 / Diabetes Mellitus, Type 2 / Diabetic Nephropathies / Albuminuria / Angiotensin Receptor Antagonists / Hypertension Type of study: Clinical_trials / Guideline Limits: Humans Language: En Journal: Blood Purif Year: 2016 Document type: Article Affiliation country: United States Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google